129075-73-6 Usage
Uses
Used in Pharmaceutical Industry:
3,4-dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone is used as a PARP inhibitor for its potential therapeutic applications in cancer treatment. It targets PARP enzymes, which are involved in DNA repair and apoptosis, making it a promising candidate for the development of anticancer drugs.
Used in Research and Development:
In the field of research, 3,4-dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone is used as a reagent for the inhibition of PARP. It helps scientists study the role of PARP enzymes in various cellular processes and their potential as therapeutic targets.
Used in In Vivo Studies:
DPQ has been utilized as a PARP1 inhibitor in in vivo studies to determine the loss of γ-H2AX (H2A histone family member X) upon irradiation. This application aids in understanding the mechanisms of DNA damage response and the potential of PARP inhibitors in radiation therapy.
Biochem/physiol Actions
3,4-Dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) is known to decrease the PARP 1 (poly(ADP-ribose) polymerase 1) mediated apoptosis under the influence of ischemia. It is considered as more effective inhibitor than the traditionally used PARP1 inhibitor 3-aminobenzamide.
Check Digit Verification of cas no
The CAS Registry Mumber 129075-73-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,9,0,7 and 5 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 129075-73:
(8*1)+(7*2)+(6*9)+(5*0)+(4*7)+(3*5)+(2*7)+(1*3)=136
136 % 10 = 6
So 129075-73-6 is a valid CAS Registry Number.
InChI:InChI=1/C18H26N2O2/c21-18-16-7-6-8-17(15(16)9-10-19-18)22-14-5-4-13-20-11-2-1-3-12-20/h6-8H,1-5,9-14H2,(H,19,21)
129075-73-6Relevant academic research and scientific papers
The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH
Chen, Kaixuan,Jiang, Zhenzhou,Liu, Shuwen,Xi, Baomin,Yang, Fubiao,Zeng, Li-Yan,Zeng, Yunong
, (2020/09/18)
Based on the SAR of both α1-AR antagonists and 5α-reductase (5AR) inhibitors, the dual-acting agent 4-(1-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-1H-indol-3-yl)butanoic acid 4aaa was designed against BPH and synthesized by two steps of N-alkylation. One-pot protocol towards 4aaa was newly developed. With IL [C6min]Br as solvent, the yield of 4aaa was increased to 75.1% from 16.0% and the reaction time was shortened in 1.5 h from 48 h. 25 derivatives structurally based on arylpiperazine and indolyl butyric acid with alkyl linker were prepared. The protocol was futher extended to get another 14 derivatives wherein O-alkylation was involved, and applied to the synthesis of biologically efficient molecules DPQ and Aripiprazole. Expectedly, compound 4aaa exhibited dual inhibition of α1-AR and 5α-reductase, and exhibited no obvious cytotoxicity against human cells. The pharmacokinetic properties of 4aaa was also determined.
Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
-
, (2008/06/13)
The invention is selected, novel, and known analogs of isoquinolinones of the formula and pharmaceutically acceptable salts thereof; novel pharmaceutical compositions; and a method for enhancing the lethal effects for tumor cells to treatment having DNA damaging activity such as ionizing radiation or with chemotherapeutic agents.
